Trial Profile
Detection, Monitoring, and Molecular Characterization of Leukemic Stem Cells From Patients With Chronic Myeloid Leukemia (CML) Undergoing Therapy With Nilotinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2022
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 29 Jul 2021 Status changed from active, no longer recruiting to completed.
- 24 Aug 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 24 Aug 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.